Nexvet charts Q1 loss, hires animal health veteran to lead development; Affymetrix strikes genomics deal with Zoetis; Kindred's Q1 loss widens;

> Nexvet ($NVET) reported that its net loss in the first quarter was $2.7 million, compared to $1.5 million in the same period a year ago. The company also hired former Eli Lilly ($LLY) and Novartis ($NVS) Animal Health executive Jürgen Horn as its chief product development officer. Earnings release | Hiring release

> Affymetrix ($AFFX) bought Eureka Genomics for $15 million and simultaneously formed a multiyear agreement to grant Zoetis ($ZTS) preferred rights to incorporate some of Eureka's technologies into its genomic products for cattle and sheep. Release

> Kindred Biosciences ($KIN) reported a first-quarter net loss of $6.7 million, or $0.34 per share, vs. a net loss of $6.2 million or $0.38 per share in the same quarter a year ago. Release

> Researchers at the University of Edinburgh published a study showing that higher levels of vitamin D were linked to better survival chances in hospitalized cats. Release

> Kane Biotech, a maker of biofilms for the human and animal health markets, announced that CEO Gord Froehlich has retired and been replaced by Mark Ahrens-Townsend. Release

> OC Raw Dog has recalled 2,055 pounds of its Turkey & Produce Raw Frozen Canine Formulation because of possible Salmonella contamination. Release

> Researchers at Washington State University's Paul G. Allen School for Global Animal Health have published a study showing a strong association between the number of illnesses among family members on Kenyan farms and the frequency of livestock sicknesses and deaths in the same household. Release

Suggested Articles

Pfizer spinoff Zoetis met Q2 expectations and brightened its full-year forecast, but it's looking to M&A to drive further growth.

Fresenius’ new CEO has pulled off a dealmaking double play, committing more than $5.4 billion to expand its reach in both sterile generics and in biosimilars.

Bayer’s pharma products have been growing lickety-split, and its 2016 numbers show just how—and how much. But with the big Monsanto merger top of mind at Bayer…